20m 39 9m

Oh My Green tosses together $20m
Stanford-Start X Fund has put its weight behind Oh My Green's seed round, which also attracted a host of venture capital firms.
Garrison rallies for $30m
Cybersecurity technology developer Garrison has received $5m from IP Group after being backed by Touchstone in 2015 and 2017.
Glympse Bio engineers $22m series A
Glympse Bio, a medical diagnostic sensor spinout from MIT, has secured $22m in a series A round ahead of clinical trials targeting fatty liver disease and cancer.
Modis modulates $30m series A
Partly based on Columbia University research, Modis is advancing treatments for rare diseases caused by dysfunction in cellular mitochondria.
Licious catches $25m
UCLA co-led the online meat and fish merchant's series C round, which included Bertelsmann, Sistema Asia and Vertex Ventures.
IDx eyes $33m
University of Iowa's medical diagnostics spinout IDx has collected $33m from investors including Optum, bringing the company’s total to $48m.
Immune-Onc books $33m series B
Immune-Onc, an immuno-oncology therapy developer exploiting University of Texas research, has received more than $33m from investors including Stanford-StartX fund.
Corelight spots $25m series B
UC Berkeley cybersecurity spinout Corelight has added General Catalyst to earlier investors including Accel Partners to bring its total funding to $34.2m.

Other News

AutoGrid charges $32m series D
AutoGrid, the distributed energy management platform backed by Stanford, will use the capital from the Eon, CLP, Innogy, Total, Ørsted and Tenaska-backed round to boost hiring.
PhaseBio attracts $34m in series D round
Existing backers AstraZeneca and Johnson & Johnson returned for a round that will advance PhaseBio's orphan disease drug pipeline, based on research from Duke University.
SkyRyse glides steady with $25m
Air transit assistance system startup SkyRyse has accrued $25m in seed and series A funding from investors including Stanford University.
Genomics detects $32.5m series B
Vertex Pharmaceuticals has led a series B round for Genomics, a spinout from University of Oxford that also attracted Oxford Sciences Innovation and IP Group.
Millendo overtakes OvaScience in merger deal
Endocrine disease therapy developer Millendo, spun out of University of Michigan, will merge with publicly-listed OvaScience, raising a further $30m in the process.

Editor's Picks

Tel Aviv partners with Tata
Tel Aviv University announces $20m commercialisation fund with Tata Industries.
UK graphene research nets $35m backing
Cell Medica raises $26.5m
Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.
Revolymer sticks to AIM in IPO
Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.
test reg

Login

Not yet subscribed?

See your subscription offers here